FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010265110> ?p ?o ?g. }

• W3010265110 endingPage "1288" @default.
• W3010265110 startingPage "1276" @default.
• W3010265110 abstract "Abstract Background Although clinical trials testing immunotherapies in glioblastoma (GBM) have yielded mixed results, new strategies targeting tumor-specific somatic coding mutations, termed “neoantigens,” represent promising therapeutic approaches. We characterized the microenvironment and neoantigen landscape of the aggressive CT2A GBM model in order to develop a platform to test combination checkpoint blockade and neoantigen vaccination. Methods Flow cytometric analysis was performed on intracranial CT2A and GL261 tumor-infiltrating lymphocytes (TILs). Whole-exome DNA and RNA sequencing of the CT2A murine GBM was employed to identify expressed, somatic mutations. Predicted neoantigens were identified using the pVAC-seq software suite, and top-ranking candidates were screened for reactivity by interferon-gamma enzyme linked immunospot assays. Survival analysis was performed comparing neoantigen vaccination, anti-programmed cell death ligand 1 (αPD-L1), or combination therapy. Results Compared with the GL261 model, CT2A exhibited immunologic features consistent with human GBM including reduced αPD-L1 sensitivity and hypofunctional TILs. Of the 29 CT2A neoantigens screened, we identified neoantigen-specific CD8+ T-cell responses in the intracranial TIL and draining lymph nodes to two H2-Kb restricted (Epb4H471L and Pomgnt1R497L) and one H2-Db restricted neoantigen (Plin2G332R). Survival analysis showed that therapeutic neoantigen vaccination with Epb4H471L, Pomgnt1R497L, and Plin2G332R, in combination with αPD-L1 treatment was superior to αPD-L1 alone. Conclusions We identified endogenous neoantigen specific CD8+ T cells within an αPD-L1 resistant murine GBM and show that neoantigen vaccination significantly augments survival benefit in combination with αPD-L1 treatment. These observations provide important preclinical correlates for GBM immunotherapy trials and support further investigation into the effects of multimodal immunotherapeutic interventions on antiglioma immunity. Key Points 1. Neoantigen vaccines combined with checkpoint blockade may be promising treatments. 2. CT2A tumors exhibit features of human GBM microenvironments. 3. Differential scanning fluorimetry assays may complement in silico neoantigen prediction tools." @default.
• W3010265110 created "2020-03-13" @default.
• W3010265110 creator A5001972165 @default.
• W3010265110 creator A5006673204 @default.
• W3010265110 creator A5012662232 @default.
• W3010265110 creator A5046469764 @default.
• W3010265110 creator A5063300449 @default.
• W3010265110 creator A5066474659 @default.
• W3010265110 creator A5067541562 @default.
• W3010265110 creator A5074416895 @default.
• W3010265110 creator A5076166380 @default.
• W3010265110 creator A5077751908 @default.
• W3010265110 creator A5088135588 @default.
• W3010265110 date "2020-03-05" @default.
• W3010265110 modified "2023-10-18" @default.
• W3010265110 title "Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine" @default.
• W3010265110 cites W1480357432 @default.
• W3010265110 cites W1487106910 @default.
• W3010265110 cites W1607316259 @default.
• W3010265110 cites W1959444207 @default.
• W3010265110 cites W1992699637 @default.
• W3010265110 cites W2007026865 @default.
• W3010265110 cites W2025183726 @default.
• W3010265110 cites W2049553585 @default.
• W3010265110 cites W2053393698 @default.
• W3010265110 cites W2071191831 @default.
• W3010265110 cites W2073880277 @default.
• W3010265110 cites W2087751238 @default.
• W3010265110 cites W2096287682 @default.
• W3010265110 cites W2104885590 @default.
• W3010265110 cites W2107429737 @default.
• W3010265110 cites W2108234281 @default.
• W3010265110 cites W2113729674 @default.
• W3010265110 cites W2115276344 @default.
• W3010265110 cites W2119180969 @default.
• W3010265110 cites W2146290346 @default.
• W3010265110 cites W2149387197 @default.
• W3010265110 cites W2151794156 @default.
• W3010265110 cites W2155943701 @default.
• W3010265110 cites W2159454255 @default.
• W3010265110 cites W2190672185 @default.
• W3010265110 cites W2256496883 @default.
• W3010265110 cites W2271914738 @default.
• W3010265110 cites W2289712604 @default.
• W3010265110 cites W2303158491 @default.
• W3010265110 cites W2404396229 @default.
• W3010265110 cites W2410468716 @default.
• W3010265110 cites W2524525752 @default.
• W3010265110 cites W2526607882 @default.
• W3010265110 cites W2541023789 @default.
• W3010265110 cites W2580464105 @default.
• W3010265110 cites W2590497374 @default.
• W3010265110 cites W2724264513 @default.
• W3010265110 cites W2728365508 @default.
• W3010265110 cites W2749747068 @default.
• W3010265110 cites W2767198352 @default.
• W3010265110 cites W2782321008 @default.
• W3010265110 cites W2790035192 @default.
• W3010265110 cites W2791483720 @default.
• W3010265110 cites W2797855256 @default.
• W3010265110 cites W2805359783 @default.
• W3010265110 cites W2891184788 @default.
• W3010265110 cites W2900082702 @default.
• W3010265110 cites W2901714962 @default.
• W3010265110 cites W2903083041 @default.
• W3010265110 cites W2904210127 @default.
• W3010265110 cites W2904803926 @default.
• W3010265110 cites W2911752971 @default.
• W3010265110 cites W2913786357 @default.
• W3010265110 cites W2967106695 @default.
• W3010265110 doi "https://doi.org/10.1093/neuonc/noaa050" @default.
• W3010265110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7523441" @default.
• W3010265110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32133512" @default.
• W3010265110 hasPublicationYear "2020" @default.
• W3010265110 type Work @default.
• W3010265110 sameAs 3010265110 @default.
• W3010265110 citedByCount "40" @default.
• W3010265110 countsByYear W30102651102020 @default.
• W3010265110 countsByYear W30102651102021 @default.
• W3010265110 countsByYear W30102651102022 @default.
• W3010265110 countsByYear W30102651102023 @default.
• W3010265110 crossrefType "journal-article" @default.
• W3010265110 hasAuthorship W3010265110A5001972165 @default.
• W3010265110 hasAuthorship W3010265110A5006673204 @default.
• W3010265110 hasAuthorship W3010265110A5012662232 @default.
• W3010265110 hasAuthorship W3010265110A5046469764 @default.
• W3010265110 hasAuthorship W3010265110A5063300449 @default.
• W3010265110 hasAuthorship W3010265110A5066474659 @default.
• W3010265110 hasAuthorship W3010265110A5067541562 @default.
• W3010265110 hasAuthorship W3010265110A5074416895 @default.
• W3010265110 hasAuthorship W3010265110A5076166380 @default.
• W3010265110 hasAuthorship W3010265110A5077751908 @default.
• W3010265110 hasAuthorship W3010265110A5088135588 @default.
• W3010265110 hasBestOaLocation W30102651101 @default.
• W3010265110 hasConcept C126322002 @default.
• W3010265110 hasConcept C147483822 @default.
• W3010265110 hasConcept C167672396 @default.
• W3010265110 hasConcept C170493617 @default.

• next